BillionToOne, Inc. (BLLN) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-03-11

How it makes money

In 2024, medical guideline changes helped increase test volume and prices.

Revenue is generated from molecular diagnostic tests. In 2024, changes to medical guidelines enabled the company to increase both the number of tests performed and the average price per test by contracting with more insurers.

What protects it: the moat

Management claims its patented technology creates a barrier to competitors.

The company uses a patented platform to detect DNA at the single-molecule level. Management believes this, along with years of accumulated data, protects its market position.

What growth costs

Managing rapid growth requires significant expenditures on personnel and operations.

The company must invest in recruiting and training skilled technical, marketing, and sales staff. It also must allocate resources to expand its overall business and operations.

What could damage it

Failure to receive insurance or government reimbursement could impair revenue.

The company's success depends on third-party payers. If Medicare, Medicaid, or other insurers fail to provide coverage or adequate payment, the company's earnings will be harmed.

About BillionToOne, Inc.

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Other companies in Diagnostics & Research